Fundamentals Hub
▼ FY 2025 Summary Analysis
Annual report ending Dec 31, 2025Overview and Growth
In fiscal 2025, Cordyceps Sunshine Biotech Holdings Co., Ltd. recorded $1.25M of revenue, net loss of $154.82K, and an operating cash outflow of $35.84K. The $1.25M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Revenue was 0.6% below fiscal 2024 revenue of $1.25M, marking a top-line contraction. On a per-share basis, diluted EPS was $0.00, which connects the reported earnings outcome with the company’s diluted share count. The diluted weighted-average share count was 111.12M, linking total earnings with the per-share result received by shareholders. Diluted shares moved 0.0% from 111.12M in fiscal 2024, leaving the current share base higher year over year. At period end, total assets were $4.66M, framing the scale of the company’s operating and financing commitments. The revenue-to-assets relationship was 0.27x, showing the sales generated relative to the resources carried on the balance sheet.Profitability
The first profit layer was $760.74K of gross profit, the amount available after reported direct revenue costs to absorb operating expenses. The gross-profit relationship equaled 61.1% of revenue, quantifying the portion retained before operating expenses were recognized. The reported operating result was an operating loss of $141.13K, reflecting costs that exceeded gross profit. The operating loss equaled 11.3% of revenue, showing the scale of the operating deficit relative to sales. The company ended the period with a net loss of $154.82K, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 12.4% after all recognized items. EBITDA was negative $5.88K, showing a deficit before interest, taxes, depreciation, and amortization. The pretax result was a loss of $154.82K, establishing the deficit before tax effects. The pretax loss equaled 12.4% of revenue, measuring the pre-tax deficit against sales. Relative to total assets, the net loss represented 3.3%. The bottom-line deficit decreased from $226.26K in fiscal 2024 to $154.82K.Liquidity and Capital Structure
At period end, the $4.66M asset base was financed through $5.19M of liabilities and -$534.55K of equity. With total equity at -$534.55K, the company carried a negative book-capital position, increasing its reliance on liabilities and future earnings. The near-term balance sheet paired $997.74K of current assets with $5.19M of current liabilities at the reporting date. The current ratio was 0.19x; current liabilities exceeded current assets, leaving a short-term liquidity deficit. The company held $3.20K in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 0.1% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The equity-to-assets relationship was -11.5%, placing book capital against the total resource base. Liabilities represented 111.5% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 0.1% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 0.7% from $4.62M in fiscal 2024, leaving current total assets higher year over year. Compared with $37.28K in fiscal 2024, the current cash balance moved 91.4% and finished lower.Cash Flow and Earnings Quality
Operating activities used $35.84K of cash, resulting in an operating cash outflow for the year. The company shifted from generating $312.01K of operating cash in fiscal 2024 to absorbing $35.84K.
Based on the annual report for the fiscal year ending Dec 31, 2025.
Analysis generated .